Table 4.
Patient characteristics and parameters.
| Parameter | Total | Group A (N = 10) | Group B (N = 18) | Group C (N = 19) |
|---|---|---|---|---|
| Gender | ||||
| Male | 84% | 100% | 100% | 68,7% |
| Female | 16% | 0% | 0% | 31,3% |
| HIV-1 subtype | ||||
| Patients with subtype B | 69% | 80% | 64% | 67% |
| Patients with non-B subtype | 31% | 20% | 36% | 33% |
| Treatment history | ||||
| Mean duration under ART in months (mean) | 66 | 80 | 88 | 54 |
| Current active drug score (mean) | - | 1.5 | 1.3 | 0.5 |
| HIV-1 RNA [copies/ml; median] | ||||
| Baseline | 20,163 | 26,950 | 8,800 | 42,600 |
| CD4 cell counts [cells/μl; median] | ||||
| Baseline | 260 | 291 | 307 | 246 |
Patient characteristics and parameters. All patients were categorized in three groups as described throughout the article: Group A (ATV and or SQV), group B (ATV and or SQV plus L76V selecting drug LPV, APV or DRV) and group C (L76V selecting drug plus optimized backbone therapy).